An Observational Study of the Mean Duration of Trastuzumab (Herceptin) Treatment in Participants With Early or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
Status: TERMINATED
Study type: OBSERVATIONAL
Conditions: Breast Cancer
Interventions: DRUG: Trastuzumab
Sponsor: Hoffmann-La Roche